Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival.
Abdulrahman Z, Santegoets SJ, Sturm G, Charoentong P, Ijsselsteijn ME, Somarakis A, Höllt T, Finotello F, Trajanoski Z, van Egmond SL, Mustafa DAM, Welters MJP, de Miranda NFCC, van der Burg SH. Abdulrahman Z, et al. Among authors: santegoets sj. J Immunother Cancer. 2022 Feb;10(2):e004346. doi: 10.1136/jitc-2021-004346. J Immunother Cancer. 2022. PMID: 35217577 Free PMC article.
In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
Santegoets SJ, Schreurs MW, Masterson AJ, Liu YP, Goletz S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh AJ, Scheper RJ, Hooijberg E, de Gruijl TD. Santegoets SJ, et al. Cancer Immunol Immunother. 2006 Dec;55(12):1480-90. doi: 10.1007/s00262-006-0142-x. Epub 2006 Feb 9. Cancer Immunol Immunother. 2006. PMID: 16468034 Free PMC article.
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD. Santegoets SJ, et al. Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10. Cancer Immunol Immunother. 2013. PMID: 22878899 Free PMC article. Clinical Trial.
The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2-4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches.
Melief SM, Visconti VV, Doorduijn EM, Santegoets SJ. Melief SM, et al. Among authors: santegoets sj. Cancer Immunol Immunother. 2014 Oct;63(10):1105-12. doi: 10.1007/s00262-014-1532-0. Epub 2014 Mar 12. Cancer Immunol Immunother. 2014. PMID: 24619351 Free PMC article. No abstract available.
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH. Santegoets SJ, et al. Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28. Cancer Immunol Immunother. 2015. PMID: 26122357 Free PMC article.
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR. Dijkgraaf EM, et al. Among authors: santegoets sj. Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216383 Free article. Clinical Trial.
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. Dijkgraaf EM, et al. Among authors: santegoets sj. Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772. Oncotarget. 2015. PMID: 26334096 Free PMC article. Clinical Trial.
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH. Welters MJ, et al. Among authors: santegoets sj. Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307. Sci Transl Med. 2016. PMID: 27075626 Clinical Trial.
Monitoring of the Immune Dysfunction in Cancer Patients.
Santegoets SJ, Welters MJ, van der Burg SH. Santegoets SJ, et al. Vaccines (Basel). 2016 Sep 2;4(3):29. doi: 10.3390/vaccines4030029. Vaccines (Basel). 2016. PMID: 27598210 Free PMC article. Review.
Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.
Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH. Welters MJP, et al. Clin Cancer Res. 2018 Feb 1;24(3):634-647. doi: 10.1158/1078-0432.CCR-17-2140. Epub 2017 Oct 10. Clin Cancer Res. 2018. PMID: 29018052
71 results